---
schema_version: "secwatch.filing_event.v1"
accession: "0000920148-23-000036"
form_type: "8-K/A"
ticker: "LH"
cik: "0000920148"
company_name: "LABCORP HOLDINGS INC."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T19:04:02.646630+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Labcorp corrects transposed equity award values for Caveney appointment; salary $650K

## Summary
- Corrected RSU and stock option awards each valued at $67,000 (were transposed).
- Corrected performance share award value of $201,000.
- Base salary increased to $650,000 effective May 1, 2023.
- Caveney appointed EVP, President Early Development & Chief Medical and Scientific Officer.
- Role part of internal restructuring for planned spin-off of clinical development business.

## SEC filing metadata
- accession: 0000920148-23-000036
- form_type: 8-K/A
- ticker: LH
- cik: 0000920148
- company_name: LABCORP HOLDINGS INC.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/920148/000092014823000036/0000920148-23-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/920148/000092014823000036/lh-20230501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000920148-23-000036
- JSON: https://secwatch.observer/filing/0000920148-23-000036.json
- Plain text: https://secwatch.observer/filing/0000920148-23-000036.txt

## Key facts
- Executive change
  Brian J. Caveney was appointed as Executive Vice President, President Early Development & Chief Medical and Scientific Officer at LABCORP HOLDINGS INC..
  - Action: appointed
  - Role: Executive Vice President, President Early Development & Chief Medical and Scientific Officer
  source text: on May 4, 2023, Labcorp announced that Brian J. Caveney, the current Executive Vice President, President, Diagnostics and Chief Medical Officer of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Early Development & Chief Medical and Scientific Officer, effective May 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/920148/000092014823000036/0000920148-23-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.